Product News
ASCO 2023: RemeGen Exhibits Promising Results of Disitamab Vedotin in Bladder Cancer
RemeGen Co., Ltd announced the latest clinical research results on disitamab vedotin at this year's American Society of Clinical Oncology Annual Meeting.
Product News
Samsara Therapeutics Parkinson’s drug receives funding boost from The Michael J. Fox Foundation
Samsara Therapeutics announced that it has received a grant from The Michael J. Fox Foundation for Parkinson’s Research to further its research into a promising Parkinson's disease drug.
Product News
SCIEX Launches the Intabio ZT System at ASMS 2023
At ASMS 2023, SCIEX launches the Intabio ZT system, the first fully-integrated microfluidic chip-based platform combining imaged capillary isoelectric focusing separation and UV detection.
Product News
Oncodesign Services and Veritas In Silico Enter Into Business Cooperation
Oncodesign Services and Veritas In Silico Inc. announced that they have entered into a Memorandum of Understanding to respond to the needs of pharmaceutical companies seeking to develop innovative small molecule drugs targeting messenger RNA.
Product News
Samsara Therapeutics Unveils Promising Autophagy Drug Candidate
Samsara Therapeutics has announced the company’s autophagy-inducing candidate SAM001, the first agent of its class to enter clinical trials.
Product News
Gyros Protein Technologies Introduces Gyrolab Generic Cyno ADA Kit Reagents
Gyros Protein Technologies AB has announced the introduction of Gyrolab® Generic Cyno Anti-Drug Antibodies Kit Reagents, for the detection of circulating immune complexes of human IgG with cyno anti-human IgG.
Product News
Personalis, ABRCC and Criterium Announce Major Prospective Clinical Trial
Personalis, Inc. has announced it has partnered with the Academic Breast Cancer Consortium and Criterium to carry out a prospective clinical trial to evaluate the clinical performance of the NeXT Personal® test.
Product News
Pharmacogenomics Research Could Save NHS at Least £41 Million Annually
An analysis of NHS prescriptions data has revealed the huge potential for pharmacogenomics to reduce ineffective prescribing and adverse effects, which could save millions of pounds for the NHS.
Product News
Avacta Opens First Two US Clinical Investigator Sites for AVA6000 Phase 1 Clinical Study
Avacta Group plc announces the opening of the first two clinical investigator sites for the phase 1 clinical trial of AVA6000 under its US Investigational New Drug Application.
Product News
Cantargia To host R&D Day on New Clinical Results of Nadunolimab in Pancreatic Cancer
Cantargia has announced it will host an R&D Day focusing on new clinical results and biomarker data for its lead asset, the IL1RAP-binding antibody nadunolimab, in pancreatic cancer patients.
Advertisement